Objective: Many patients who undergo endovascular aneurysm repair (EVAR) will require reintervention. It remains unclear whether patients who have EVAR for symptomatic or ruptured aneurysms are more likely to require reintervention compared with patients who have EVAR electively. The objective of this study was to compare the freedom from reintervention after EVAR of patients who have their operation performed electively vs for a symptomatic or ruptured aneurysm.
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Methods: We studied all patients captured by the Vascular Quality Initiative (VQI) who underwent EVAR from 2003 to 2015 (n ¼ 17,447). We linked patients in the VQI to their respective Medicare claims file for 5-year outcome analysis. We identified reintervention events using a validated algorithm. We stratified patients into three mutually exclusive groups based on the urgency of their index operation: elective (n ¼ 15,397), symptomatic (n ¼ 1249), or ruptured (n ¼ 706). Our primary outcome was reintervention after EVAR. We assessed our primary outcome with Kaplan-Meier survival estimation and Cox regression analysis.
Results: The freedom from reintervention after EVAR was 77% at 5 years (95% confidence interval [CI], 76%-78%) for the entire cohort (Fig  1) . Freedom from reintervention was significantly different across the categories of EVAR urgency (log-rank, P < .001; Fig 2) . Patients who underwent EVAR on an elective basis had the best freedom from reintervention, 78% at 5 years (CI, 77%-79%). Those who underwent surgery for symptomatic aneurysms had a lower freedom from reintervention, 72% at 5 years (CI, 66%-77%). The crude hazard ratio of reintervention for patients who underwent surgery for symptomatic aneurysms vs elective repair was 1.36 (CI, 1.17-1.57), indicating that patients who had EVAR for symptomatic aneurysms had a 36% higher likelihood of requiring reintervention during 5 years compared with patients who had an elective operation. Patients undergoing EVAR emergently for rupture had the poorest freedom from reintervention, 63% at 5 years (CI, 55%-69%). The crude hazard ratio of reintervention for patients who underwent EVAR for rupture vs elective repair was 2.32 (CI, 1.95-2.77), indicating that patients who underwent EVAR for rupture had a more than twofold higher likelihood of undergoing reintervention during the following 5 years compared with patients who had an elective operation.
Conclusions: Nearly one in four patients will undergo reintervention after EVAR within the VQI. The need for reintervention increases 1.3-fold for symptomatic aneurysms and 2.3-fold when EVAR is performed emergently for rupture. Vigilant surveillance is warranted for patients who undergo EVAR, especially for those treated on an urgent or emergent basis. Objective: Abdominal aortic aneurysm (AAA) has an age-dependent prevalence of 2% to 11% and is a leading cause of death in men aged >65 years if it is not treated surgically. Endovascular aneurysm repair (EVAR) is performed in up to 80% of elective and 90% of ruptured cases. Although reducing perioperative, early, and midterm outcomes and complications rates, the procedure is associated with specific complications requiring close follow-up, especially endoleaks. Type II endoleaks occur in up to 30% after EVAR; however, aneurysm sac expansion is rare. In this study, we investigate the aneurysm wall morphology in secondary expanding human AAA samples after EVAR due to persistent endoleak type II in comparison to nonaneurysmatic control aortas and AAA samples.
Methods: Samples were acquired from the aneurysm sac during retroperitoneal ligation of the feeder vessel in a cohort of nine patients. Control tissues included 42 AAAs and 11 control aortas. Hematoxylin and eosin staining and immunohistochemistry for CD3/4/31/68 and Ki67 were performed for morphologic analysis and characterization. Terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling assays allowed quantification of apoptotic cells. Reverse transcription-polymerase chain reaction was used to quantify gene expression and Western blot to quantify proteins.
Results: Secondary expansion after EVAR was approximately 17% during 21 6 12 months before operation. The sac wall after expansion shows significant thinning of the intima-media layer. This is accompanied by a scarcity of cells, with only little chronic inflammation left compared with AAA samples. Macrophages are seen in abundance, and matrix metalloproteinase expression is significantly upregulated. Relevant apoptosis is not noticed. Fibrous tissue is reduced, and a collagen turnover to different subtypes is noted in comparison to nonaneurysmatic control aorta and AAA.
Conclusions: This is the first study examining aneurysm sac morphology after EVAR with persistent type II endoleak. Atrophy and proteolysis suggestive of structural weakening are observed and have to be considered indications for follow-up and treatment of this frequent EVAR complication. 
